ResearcherUniversity of TorontoActive in the last 2 years

Alberto Hernando‐Calvo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1692-1125; OpenAlex author ID A5013892733. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 6

Papers, trials and grants by year

2024: 1 paper

Papers 1

A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair-Proficient Colorectal or Pancreatic Cancer. Co-author DOI 10.1016/j.clcc.2024.05.002 ↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

María Vila-Casadesús · 1 shared paper, 2024 · strength 0.16
- Paper A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair-Prof… DOI 10.1016/j.clcc.2024.05.002 ↗
Aaron Richard Hansen · 1 shared paper, 2024 · strength 0.16
- Paper A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair-Prof… DOI 10.1016/j.clcc.2024.05.002 ↗
Benjamin Haibe‐Kains · 1 shared paper, 2024 · strength 0.16
- Paper A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair-Prof… DOI 10.1016/j.clcc.2024.05.002 ↗
Ana P. Vivancos · 1 shared paper, 2024 · strength 0.16
- Paper A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair-Prof… DOI 10.1016/j.clcc.2024.05.002 ↗
Lillian Siu · 1 shared paper, 2024 · strength 0.16
- Paper A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair-Prof… DOI 10.1016/j.clcc.2024.05.002 ↗
Philippe Lucien Bedard · 1 shared paper, 2024 · strength 0.16
- Paper A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair-Prof… DOI 10.1016/j.clcc.2024.05.002 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.